Videos

Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, The US Oncology Research, discusses exciting data seen with antiandrogen agents for the treatment of prostate cancer.

Kevin Staveley-O’Carroll, MD, PhD, discusses one of the challenges in treating patients with hepatocellular carcinoma and shares what he thinks are the next steps in overcoming this challenge.

Alexander E. Drilon, MD, discusses the next steps for LOXO-292 in 2 subsets of patients: those with RET fusion-positive cancers and <em>RET</em>-mutant medullary thyroid cancers.

Ali McBride, PharmD, MS, BCOP, discusses the theme for his presidency: Collaborate. Educate. Compensate: A Prescription for Sustainable Cancer Care Delivery.<br /> &nbsp;

Relapsed/Refractory Multiple Myeloma

Pashtoon M. Kasi, MD, MBBS, MS, discusses the patient populations with colorectal cancer that are likely to benefit from immunotherapy treatment.

Sukhmani Padda, MD, discusses the role of immunotherapy in patients with <em>EGFR</em>-positive non&ndash;small cell lung cancer.

Ramez N. Eskander, MD, discusses the current outlook for the frontline treatment landscape in ovarian cancer.

Kathleen G. Essel, MD, discusses the role of quantitative imaging feature analysis in gynecologic cancers.

Mark D. Pegram, MD, discusses how the results from the phase III KATHERINE trial will change practice for the treatment of patients with breast cancer.

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in patients with polycythemia vera.

Carla Casulo, MD, discusses recent research for new frontline options for patients with newly diagnosed follicular lymphoma.

Susan Prockop, MD, discusses an option available for the treatment of central nervous Epstein-Barr virus-positive posttransplant lymphoproliferative disease.<br /> &nbsp;

Ursula A. Matulonis, MD, discusses the survival results from an analysis of the QUADRA trial in heavily pretreated patients with recurrent ovarian cancer.

Aditya Bardia, MBBS, MPH, discusses the development of targeted therapies for patients with triple-negative breast cancer. He says these approaches can be divided into 3 different categories.

Floor J. Backes, MD,&nbsp;discusses the results from a phase I trial investigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.

Advanced Ovarian Cancer